AR084610A1 - Comprimido de desintegracion oral de lansoprazol - Google Patents
Comprimido de desintegracion oral de lansoprazolInfo
- Publication number
- AR084610A1 AR084610A1 ARP110104955A ARP110104955A AR084610A1 AR 084610 A1 AR084610 A1 AR 084610A1 AR P110104955 A ARP110104955 A AR P110104955A AR P110104955 A ARP110104955 A AR P110104955A AR 084610 A1 AR084610 A1 AR 084610A1
- Authority
- AR
- Argentina
- Prior art keywords
- fine granules
- active ingredient
- pharmaceutically active
- lansoprazole
- controlled release
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se proporciona un comprimido de desintegración oral obtenido por compresión de gránulos finos que muestran una liberación controlada de lansoprazol y un aditivo, que es capaz de suprimir la rotura de los gránulos finos durante la compresión y puede controlar la liberación de lansoprazol durante un tiempo prolongado y puede mantener una concentración terapéuticamente efectiva durante un tiempo prolongado y muestra una propiedad de desintegración en la cavidad oral. Un comprimido de desintegración oral que contiene (i) gránulos finos que muestran una liberación controlada de un ingrediente farmacéuticamente activo, que contiene gránulos finos con un ingrediente farmacéuticamente activo y una capa de recubrimiento con copolímero de ácido metacrílico/acrilato de metilo/metacrilato de metilo, en donde los gránulos finos que contienen un ingrediente farmacéuticamente activo están recubiertos con más del 80% en peso y no más del 300% en peso del copolímero y (ii) gránulos finos que muestran una liberación controlada de un ingrediente farmacéuticamente activo, que contiene el ingrediente farmacéuticamente activo y una capa de recubrimiento que comprende (a) un copolímero de acrilato de etilo/metacrilato de metilo y (b) uno o varios tipos de polímeros seleccionados del grupo que consiste en copolímero de ácido metacrílico/acrilato de etilo, ftalato de hipromelosa, carboximetiletilcelulosa, acetato ftalato de polivinilo, acetato succinato de hidroxipropilmetilcelulosa y acetato ftalato de celulosa, en donde los gránulos finos (i) y gránulos finos (ii) tienen un tamaño de partícula medio de no más del 500 mm y el ingrediente farmacéuticamente activo es lansoprazol o una de sus formas ópticamente activos o una de sus sales.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201061427384P | 2010-12-27 | 2010-12-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR084610A1 true AR084610A1 (es) | 2013-05-29 |
Family
ID=45509604
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP110104955A AR084610A1 (es) | 2010-12-27 | 2011-12-27 | Comprimido de desintegracion oral de lansoprazol |
Country Status (23)
Country | Link |
---|---|
US (1) | US20130273157A1 (es) |
EP (1) | EP2658530A2 (es) |
JP (1) | JP2014501224A (es) |
KR (1) | KR20140007364A (es) |
CN (1) | CN103402500A (es) |
AR (1) | AR084610A1 (es) |
AU (1) | AU2011350396A1 (es) |
BR (1) | BR112013014875A2 (es) |
CA (1) | CA2823166C (es) |
CL (1) | CL2013001793A1 (es) |
CO (1) | CO6731132A2 (es) |
CR (1) | CR20130327A (es) |
EA (1) | EA028217B1 (es) |
EC (1) | ECSP13012718A (es) |
MA (1) | MA34768B1 (es) |
MX (1) | MX2013007588A (es) |
PE (1) | PE20141115A1 (es) |
SG (2) | SG190905A1 (es) |
TN (1) | TN2013000220A1 (es) |
TW (1) | TW201304823A (es) |
UY (1) | UY33841A (es) |
WO (1) | WO2012091153A2 (es) |
ZA (1) | ZA201304617B (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY31698A (es) | 2008-03-11 | 2009-11-10 | Takeda Pharmaceutical | Preparacion solida de desintegracion oral |
ES2963218T3 (es) | 2011-12-28 | 2024-03-25 | Global Blood Therapeutics Inc | Productos intermedios para obtener compuestos de benzaldehído sustituidos y métodos para su uso en el aumento de la oxigenación tisular |
WO2013102145A1 (en) | 2011-12-28 | 2013-07-04 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
GB201303781D0 (en) | 2013-03-04 | 2013-04-17 | Gauthier Pierre Pascal | Oral timer device and method of using same |
US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
CN111454200A (zh) | 2013-03-15 | 2020-07-28 | 全球血液疗法股份有限公司 | 化合物及其用于调节血红蛋白的用途 |
CA2902711C (en) | 2013-03-15 | 2021-07-06 | Global Blood Therapeutics, Inc. | Substituted pyridinyl-6-methoxy-2-hydroxybenzaldehyde derivatives and pharmaceutical compositions thereof useful for the modulation of hemoglobin |
US20160083343A1 (en) | 2013-03-15 | 2016-03-24 | Global Blood Therapeutics, Inc | Compounds and uses thereof for the modulation of hemoglobin |
US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
CA2916564C (en) | 2014-02-07 | 2023-02-28 | Global Blood Therapeutics, Inc. | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
AU2015346037A1 (en) | 2014-11-14 | 2017-07-06 | Gemphire Therapeutics Inc. | Processes and intermediates for preparing alpha,omega-dicarboxylic acid-terminated dialkane ethers |
EP3288556A4 (en) | 2015-04-29 | 2018-09-19 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
SG10201912511WA (en) | 2015-12-04 | 2020-02-27 | Global Blood Therapeutics Inc | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
TWI663160B (zh) | 2016-05-12 | 2019-06-21 | 全球血液治療公司 | 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法 |
US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
TWI778983B (zh) * | 2016-10-12 | 2022-10-01 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
WO2018209257A1 (en) * | 2017-05-11 | 2018-11-15 | Gemphire Therapeutics Inc. | Gemcabene compositions and methods of use thereof |
SG11202000136YA (en) * | 2017-07-10 | 2020-02-27 | Takeda Pharmaceuticals Co | Preparation comprising vonoprazan |
CN108576205B (zh) * | 2018-03-22 | 2022-01-04 | 湖北省农业科学院农产品加工与核农技术研究所 | 一种草莓联合干燥的处理方法 |
US11014884B2 (en) | 2018-10-01 | 2021-05-25 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6150978A (ja) | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | ピリジン誘導体およびその製造法 |
JPH072761B2 (ja) | 1985-03-20 | 1995-01-18 | 不二パウダル株式会社 | 微結晶セルロ−ス球形顆粒及びその製造法 |
JPS62277322A (ja) | 1986-02-13 | 1987-12-02 | Takeda Chem Ind Ltd | 安定化された腸溶性抗潰瘍固形組成物 |
FR2679451B1 (fr) | 1991-07-22 | 1994-09-09 | Prographarm Laboratoires | Comprime multiparticulaire a delitement rapide. |
JP3069458B2 (ja) | 1992-01-29 | 2000-07-24 | 武田薬品工業株式会社 | 口腔内崩壊型錠剤およびその製造法 |
JP2919771B2 (ja) | 1995-04-17 | 1999-07-19 | 佐藤製薬株式会社 | 速溶解性錠剤の製造方法及び該製造方法により製造した速溶解性錠剤 |
JPH0948726A (ja) | 1995-08-07 | 1997-02-18 | Tanabe Seiyaku Co Ltd | 口腔内速崩壊性製剤およびその製法 |
TW385306B (en) | 1996-11-14 | 2000-03-21 | Takeda Chemical Industries Ltd | Method for producing crystals of benzimidazole derivatives |
JP3828648B2 (ja) | 1996-11-14 | 2006-10-04 | 武田薬品工業株式会社 | 2−(2−ピリジルメチルスルフィニル)ベンズイミダゾール系化合物の結晶およびその製造法 |
ES2559766T3 (es) | 1998-05-18 | 2016-02-15 | Takeda Pharmaceutical Company Limited | Comprimidos disgregables en la boca |
AR019935A1 (es) | 1998-07-28 | 2002-03-27 | Takeda Pharmaceutical | Preparacion solida de desintegracion rapida, uso de una hidroxipropil celulosa poco sustituida en dicha preparacion y metodo para mejorar la capacidad dedesintegracion rapida de la misma |
TWI275587B (en) | 1999-06-17 | 2007-03-11 | Takeda Chemical Industries Ltd | A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole |
AU2001252595A1 (en) | 2000-04-28 | 2001-11-12 | Takeda Chemical Industries Ltd. | Process for producing optically active sulfoxide derivative |
ES2511774T3 (es) | 2000-05-15 | 2014-10-23 | Takeda Pharmaceutical Company Limited | Formas cristalinas de (R)-lansoprazol |
DK1337525T3 (da) | 2000-12-01 | 2011-09-19 | Takeda Pharmaceutical | Fremgangsmåde til krystallisering af (R)- eller (S)-lansoprazol |
JP4493970B2 (ja) | 2002-10-16 | 2010-06-30 | 武田薬品工業株式会社 | 持続性製剤 |
WO2005092297A2 (en) * | 2004-03-03 | 2005-10-06 | Teva Pharmaceutical Industries Ltd. | A stable pharmaceutical composition comprising an acid labile drug |
US20070141151A1 (en) * | 2005-12-20 | 2007-06-21 | Silver David I | Lansoprazole orally disintegrating tablets |
CN101340897A (zh) * | 2005-12-20 | 2009-01-07 | 特瓦制药工业有限公司 | 兰索拉唑口腔崩解片剂 |
EP1837016A3 (en) * | 2006-03-08 | 2008-01-02 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical multiple-unit composition |
EP2098250B1 (en) * | 2006-12-28 | 2016-09-28 | Takeda Pharmaceutical Company Limited | Orally disintegrating solid preparation |
UY31698A (es) * | 2008-03-11 | 2009-11-10 | Takeda Pharmaceutical | Preparacion solida de desintegracion oral |
WO2010008569A1 (en) * | 2008-07-17 | 2010-01-21 | Barr Laboratories, Inc. | Orally disintegrating solid pharmaceutical dosage forms comprising delayed-release lansoprazole and methods of making and using the same |
-
2011
- 2011-12-26 CN CN2011800685821A patent/CN103402500A/zh active Pending
- 2011-12-26 MX MX2013007588A patent/MX2013007588A/es not_active Application Discontinuation
- 2011-12-26 SG SG2013040944A patent/SG190905A1/en unknown
- 2011-12-26 US US13/997,862 patent/US20130273157A1/en not_active Abandoned
- 2011-12-26 BR BR112013014875A patent/BR112013014875A2/pt active Search and Examination
- 2011-12-26 EP EP11811174.9A patent/EP2658530A2/en not_active Withdrawn
- 2011-12-26 UY UY0001033841A patent/UY33841A/es not_active Application Discontinuation
- 2011-12-26 SG SG10201602311XA patent/SG10201602311XA/en unknown
- 2011-12-26 WO PCT/JP2011/080568 patent/WO2012091153A2/en active Application Filing
- 2011-12-26 KR KR1020137019795A patent/KR20140007364A/ko not_active Application Discontinuation
- 2011-12-26 AU AU2011350396A patent/AU2011350396A1/en not_active Abandoned
- 2011-12-26 CA CA2823166A patent/CA2823166C/en active Active
- 2011-12-26 PE PE2013001471A patent/PE20141115A1/es not_active Application Discontinuation
- 2011-12-26 EA EA201390981A patent/EA028217B1/ru not_active IP Right Cessation
- 2011-12-26 TW TW100148775A patent/TW201304823A/zh unknown
- 2011-12-26 JP JP2013529237A patent/JP2014501224A/ja active Pending
- 2011-12-27 AR ARP110104955A patent/AR084610A1/es unknown
-
2013
- 2013-05-24 TN TNP2013000220A patent/TN2013000220A1/fr unknown
- 2013-06-19 CL CL2013001793A patent/CL2013001793A1/es unknown
- 2013-06-21 ZA ZA2013/04617A patent/ZA201304617B/en unknown
- 2013-06-25 EC ECSP13012718 patent/ECSP13012718A/es unknown
- 2013-06-27 CR CR20130327A patent/CR20130327A/es not_active Application Discontinuation
- 2013-06-28 MA MA36063A patent/MA34768B1/fr unknown
- 2013-07-25 CO CO13176405A patent/CO6731132A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
KR20140007364A (ko) | 2014-01-17 |
WO2012091153A3 (en) | 2012-09-07 |
EP2658530A2 (en) | 2013-11-06 |
BR112013014875A2 (pt) | 2016-10-18 |
CR20130327A (es) | 2013-08-22 |
TN2013000220A1 (en) | 2014-11-10 |
PE20141115A1 (es) | 2014-09-12 |
JP2014501224A (ja) | 2014-01-20 |
EA028217B1 (ru) | 2017-10-31 |
CO6731132A2 (es) | 2013-08-15 |
WO2012091153A2 (en) | 2012-07-05 |
SG190905A1 (en) | 2013-07-31 |
CN103402500A (zh) | 2013-11-20 |
EA201390981A1 (ru) | 2014-07-30 |
CL2013001793A1 (es) | 2013-12-06 |
CA2823166A1 (en) | 2012-07-05 |
MA34768B1 (fr) | 2013-12-03 |
ZA201304617B (en) | 2014-08-27 |
ECSP13012718A (es) | 2013-12-31 |
MX2013007588A (es) | 2013-08-09 |
CA2823166C (en) | 2019-04-09 |
AU2011350396A1 (en) | 2013-07-11 |
US20130273157A1 (en) | 2013-10-17 |
TW201304823A (zh) | 2013-02-01 |
SG10201602311XA (en) | 2016-04-28 |
UY33841A (es) | 2012-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR084610A1 (es) | Comprimido de desintegracion oral de lansoprazol | |
ES2509117T3 (es) | Composición farmacéutica oral que contiene dabigatran etexilato | |
PE20091620A1 (es) | Preparacion solida de desintegracion oral | |
PE20131126A1 (es) | Forma de dosificacion resistente a alteracion que comprende un polimero anionico | |
JP2013522219A5 (es) | ||
AR094548A1 (es) | Dispersión sólida físicamente estable | |
CL2016001424A1 (es) | Composiciones de liberación retardada de lionaclotida | |
EA201290596A1 (ru) | Фармацевтический состав, содержащий один или более эфиров фумаровой кислоты в разлагаемой матрице | |
EP4233978A3 (en) | Oral delivery of active drug substances | |
TR201010683A1 (tr) | Vildagliptin formülasyonları. | |
RU2008130892A (ru) | Твердое лекарственное средство с контролируемым высвобождением | |
NZ605601A (en) | Pharmaceutical composition comprising amide derivative or pharmaceutically acceptable salt thereof | |
CO6640256A2 (es) | Tableta enterica | |
AR102228A1 (es) | Una formulación de metformina de liberación sostenida y un método de preparación de la misma | |
EA201400737A1 (ru) | Система доставки на основе множества пеллет с немедленным высвобождением активного вещества | |
CO6382109A2 (es) | Formulación de depósito de octreotida con niveles de exposición constantemente altos | |
CL2017001186A1 (es) | Comprimido multicapa que contiene un fármaco inestable a la luz | |
EA201270581A1 (ru) | Фармацевтические композиции севеламера | |
ES2623281T3 (es) | Composiciones farmacéuticas sólidas con recubrimiento entérico para inhibidores de la bomba de protones. | |
AR071970A1 (es) | Composicion de liberacion pulsatil de sildenafil y proceso para prepararla | |
BR112015023381A2 (pt) | composição de liberação imediata de sovaprevir, composição de sovaprevir de 200 mg, núcleo de comprimido de sovaprevir e comprimido de sovaprevir revestido | |
WO2012074830A3 (en) | Modified release tranexamic acid formulation | |
AR071706A1 (es) | Una formulacion farmaceutica de cilostazol solida de liberacion sostenida y metodo de preparacion. | |
RU2012151315A (ru) | Энтеросолюбильная таблетка | |
EA201490500A1 (ru) | Многослойный высвобождающий состав |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |